BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

112 related articles for article (PubMed ID: 33070871)

  • 1. Friends and foes: Our evolving understanding of the link between Fbxw7 and p53 in cancer.
    Elizabeth Caldon C
    Neoplasia; 2020 Nov; 22(11):659-660. PubMed ID: 33070871
    [No Abstract]   [Full Text] [Related]  

  • 2. Primary cutaneous diffuse large B-cell lymphoma presenting as a solitary subcutaneous nodule with TP53 and FBXW7 mutations.
    Yoshimoto N; Yanagi T; Matsumura W; Ujiie I; Izumi K; Ando S; Nishie W; Fujii K; Nishihara H; Shimizu H
    Int J Dermatol; 2017 Dec; 56(12):1459-1461. PubMed ID: 28960258
    [No Abstract]   [Full Text] [Related]  

  • 3. Alteration of tumor suppressors changes the endometrial tumor spectrum.
    Mayo LD
    EMBO Mol Med; 2023 Oct; 15(10):e18166. PubMed ID: 37587857
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Colorectal Cancer Stem Cells Acquire Chemoresistance Through the Upregulation of F-Box/WD Repeat-Containing Protein 7 and the Consequent Degradation of c-Myc.
    Izumi D; Ishimoto T; Miyake K; Eto T; Arima K; Kiyozumi Y; Uchihara T; Kurashige J; Iwatsuki M; Baba Y; Sakamoto Y; Miyamoto Y; Yoshida N; Watanabe M; Goel A; Tan P; Baba H
    Stem Cells; 2017 Sep; 35(9):2027-2036. PubMed ID: 28699179
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Fbxw7 haploinsufficiency loses its protection against DNA damage and accelerates MNU-induced gastric carcinogenesis.
    Jiang Y; Qi X; Liu X; Zhang J; Ji J; Zhu Z; Ren J; Yu Y
    Oncotarget; 2017 May; 8(20):33444-33456. PubMed ID: 28422719
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The FOXA2 transcription factor is frequently somatically mutated in uterine carcinosarcomas and carcinomas.
    Le Gallo M; Rudd ML; Urick ME; Hansen NF; ; Merino MJ; Mutch DG; Goodfellow PJ; Mullikin JC; Bell DW
    Cancer; 2018 Jan; 124(1):65-73. PubMed ID: 28940304
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Fbxw7/Cdc4 is a p53-dependent, haploinsufficient tumour suppressor gene.
    Mao JH; Perez-Losada J; Wu D; Delrosario R; Tsunematsu R; Nakayama KI; Brown K; Bryson S; Balmain A
    Nature; 2004 Dec; 432(7018):775-9. PubMed ID: 15592418
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Establishment and analysis of a novel mouse line carrying a conditional knockin allele of a cancer-specific FBXW7 mutation.
    Ikenoue T; Terakado Y; Zhu C; Liu X; Ohsugi T; Matsubara D; Fujii T; Kakuta S; Kubo S; Shibata T; Yamaguchi K; Iwakura Y; Furukawa Y
    Sci Rep; 2018 Jan; 8(1):2021. PubMed ID: 29386660
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The role of FBXW7, a cell-cycle regulator, as a predictive marker of recurrence of gastrointestinal stromal tumors.
    Koga Y; Iwatsuki M; Yamashita K; Kiyozumi Y; Kurashige J; Masuda T; Eto K; Iwagami S; Harada K; Ishimoto T; Baba Y; Yoshida N; Miyanari N; Takamori H; Ajani JA; Baba H
    Gastric Cancer; 2019 Nov; 22(6):1100-1108. PubMed ID: 30854619
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The WD40 domain of FBXW7 is a poly(ADP-ribose)-binding domain that mediates the early DNA damage response.
    Zhang Q; Mady ASA; Ma Y; Ryan C; Lawrence TS; Nikolovska-Coleska Z; Sun Y; Morgan MA
    Nucleic Acids Res; 2019 May; 47(8):4039-4053. PubMed ID: 30722038
    [TBL] [Abstract][Full Text] [Related]  

  • 11. FBXW7 circular RNA regulates proliferation, migration and invasion of colorectal carcinoma through NEK2, mTOR, and PTEN signaling pathways in vitro and in vivo.
    Lu H; Yao B; Wen X; Jia B
    BMC Cancer; 2019 Sep; 19(1):918. PubMed ID: 31519156
    [TBL] [Abstract][Full Text] [Related]  

  • 12. MiR-223 promotes the doxorubicin resistance of colorectal cancer cells via regulating epithelial-mesenchymal transition by targeting FBXW7.
    Ding J; Zhao Z; Song J; Luo B; Huang L
    Acta Biochim Biophys Sin (Shanghai); 2018 Jun; 50(6):597-604. PubMed ID: 29701752
    [TBL] [Abstract][Full Text] [Related]  

  • 13.
    Sadigh S; Morrissette JJD; Bagg A
    Leuk Lymphoma; 2019 Jun; 60(6):1601-1602. PubMed ID: 30632836
    [No Abstract]   [Full Text] [Related]  

  • 14. FBXW7 expression is associated with prognosis and chemotherapeutic outcome in Chinese patients with gastric adenocarcinoma.
    Li MR; Zhu CC; Ling TL; Zhang YQ; Xu J; Zhao EH; Zhao G
    BMC Gastroenterol; 2017 May; 17(1):60. PubMed ID: 28464881
    [TBL] [Abstract][Full Text] [Related]  

  • 15. miR-92b-3p Promotes Colorectal Carcinoma Cell Proliferation, Invasion, and Migration by Inhibiting FBXW7 In Vitro and In Vivo.
    Gong L; Ren M; Lv Z; Yang Y; Wang Z
    DNA Cell Biol; 2018 May; 37(5):501-511. PubMed ID: 29638162
    [TBL] [Abstract][Full Text] [Related]  

  • 16. FBXW7 deletion contributes to lung tumor development and confers resistance to gefitinib therapy.
    Xiao Y; Yin C; Wang Y; Lv H; Wang W; Huang Y; Perez-Losada J; Snijders AM; Mao JH; Zhang P
    Mol Oncol; 2018 Jun; 12(6):883-895. PubMed ID: 29633504
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Epithelial-Myoepithelial Carcinoma: Frequent Morphologic and Molecular Evidence of Preexisting Pleomorphic Adenoma, Common HRAS Mutations in PLAG1-intact and HMGA2-intact Cases, and Occasional TP53, FBXW7, and SMARCB1 Alterations in High-grade Cases.
    El Hallani S; Udager AM; Bell D; Fonseca I; Thompson LDR; Assaad A; Agaimy A; Luvison AM; Miller C; Seethala RR; Chiosea S
    Am J Surg Pathol; 2018 Jan; 42(1):18-27. PubMed ID: 29135520
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The FBXW7 tumor suppressor inhibits breast cancer proliferation and promotes apoptosis by targeting MTDH for degradation.
    Chen X; Li XY; Long M; Wang X; Gao ZW; Cui Y; Ren J; Zhang Z; Liu C; Dong K; Zhang H
    Neoplasma; 2018; 65(2):201-209. PubMed ID: 29534580
    [TBL] [Abstract][Full Text] [Related]  

  • 19. E3 ligase FBXW7 aggravates TMPD-induced systemic lupus erythematosus by promoting cell apoptosis.
    Chong Z; Bao C; He J; Chen T; Zhong L; Li G; Li H; Fang L; Song Y; Fu G; Yang X; Lai L; Liu Y; Wang Q
    Cell Mol Immunol; 2018 Dec; 15(12):1057-1070. PubMed ID: 30275535
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Targeted sequencing reveals TP53 as a potential diagnostic biomarker in the post-treatment surveillance of head and neck cancer.
    van Ginkel JH; de Leng WW; de Bree R; van Es RJ; Willems SM
    Oncotarget; 2016 Sep; 7(38):61575-61586. PubMed ID: 27528217
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.